Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response

Patients with metastatic HER2 breast cancer (MBC) often become resistant to HER 2 targeted therapy and have recurrence of disease. The Panacea trial suggested that HER2 MBC patients were more likely to respond to checkpoint therapy if TIL were present or if tumor expressed PD-L1. We assessed whether...

Descripción completa

Detalles Bibliográficos
Autores principales: Kodumudi, Krithika N., Ramamoorthi, Ganesan, Snyder, Colin, Basu, Amrita, Jia, Yongsheng, Awshah, Sabrina, Beyer, Amber P., Wiener, Doris, Lam, Lian, Zhang, Hongtao, Greene, Mark I., Costa, Ricardo L. B., Czerniecki, Brian J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702967/
https://www.ncbi.nlm.nih.gov/pubmed/31475002
http://dx.doi.org/10.3389/fimmu.2019.01939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702967/
https://www.ncbi.nlm.nih.gov/pubmed/31475002
http://dx.doi.org/10.3389/fimmu.2019.01939

Ejemplares similares